Open veterinary journal · 2026
Hypofractionated reirradiation for feline nasal epithelial tumors: A retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ueno Hirona, Kondo Yui, Nishiyama Yuta, Katayama Takayuki, Banno Yusuke, Kayanuma Hideki, Maruo Takuya
Аннотация
BACKGROUND: Feline nasal epithelial tumors are locally invasive and radiosensitive, and radiotherapy is the standard treatment. However, recurrence is common, and the role of reirradiation in cats remains unclear.
AIM: This retrospective study aimed to evaluate the efficacy and safety of hypofractionated reirradiation in cats with recurrent nasal epithelial tumors.
METHODS: The medical records of cats treated with hypofractionated radiotherapy for intranasal epithelial tumors at Azabu University Veterinary Teaching Hospital between 2014 and 2022 were reviewed. Follow-up continued until August 2023.
RESULTS: Twenty-six cats were treated, 11 of which underwent reirradiation after clinical progression. The median interval between treatments was 356 days. In the first course, responses included complete (n = 1), partial (n = 7), stable (n = 16), and progressive (n = 2) diseases. In the second course, all cats achieved stable disease. The median overall survival was significantly longer in the reirradiation group than in the nonreirradiation group (562 vs. 58 days, p < 0.001). Although not statistically significant (p = 0.08), adenocarcinomas tended to have longer OS than squamous cell carcinomas. Acute adverse events (Veterinary Radiation Therapy Oncology Group grade 1-2), including conjunctivitis, alopecia, and dermatitis, were observed. Late adverse events, such as leukotrichia and hyperpigmentation, did not affect survival. Two cats developed grade 3 late toxicities (cutaneous or oral-cutaneous-nasal fistulas) associated with bone lysis and short inter-treatment intervals.
CONCLUSION: Hypofractionated reirradiation may be a viable salvage option for feline nasal epithelial tumors, particularly in cases with adenocarcinoma or early-stage disease, with acceptable toxicity when patients are carefully selected.
AIM: This retrospective study aimed to evaluate the efficacy and safety of hypofractionated reirradiation in cats with recurrent nasal epithelial tumors.
METHODS: The medical records of cats treated with hypofractionated radiotherapy for intranasal epithelial tumors at Azabu University Veterinary Teaching Hospital between 2014 and 2022 were reviewed. Follow-up continued until August 2023.
RESULTS: Twenty-six cats were treated, 11 of which underwent reirradiation after clinical progression. The median interval between treatments was 356 days. In the first course, responses included complete (n = 1), partial (n = 7), stable (n = 16), and progressive (n = 2) diseases. In the second course, all cats achieved stable disease. The median overall survival was significantly longer in the reirradiation group than in the nonreirradiation group (562 vs. 58 days, p < 0.001). Although not statistically significant (p = 0.08), adenocarcinomas tended to have longer OS than squamous cell carcinomas. Acute adverse events (Veterinary Radiation Therapy Oncology Group grade 1-2), including conjunctivitis, alopecia, and dermatitis, were observed. Late adverse events, such as leukotrichia and hyperpigmentation, did not affect survival. Two cats developed grade 3 late toxicities (cutaneous or oral-cutaneous-nasal fistulas) associated with bone lysis and short inter-treatment intervals.
CONCLUSION: Hypofractionated reirradiation may be a viable salvage option for feline nasal epithelial tumors, particularly in cases with adenocarcinoma or early-stage disease, with acceptable toxicity when patients are carefully selected.